By Bill Berkrot and Ransdell Pierson NEW YORK (Reuters) - After decades of Alzheimer’s research that led to dead ends, including 123 drugs that failed, top researchers in the field say they are far more confident now of producing an effective treatment. Their optimism has been building ahead of the Alzheimer's Association International Conference (AAIC), which starts on Saturday in Washington, DC. New experimental drugs from Eli Lilly and Co and Biogen have shown promise in slowing down the progression of the mind-wasting disease, attracting the attention of investors and patients. Those drugs are still very early in their development and could still join the scrap heap. But the field has gained a major understanding of how the brain changes with Alzheimer’s and better insight on how and when to intervene medically. "The recurring platitude, which has been going on forever is 'gee we're about five years away from a really effective treatment,'" said Steven Ferris, who directs the Alzheimer's clinical trials program at NYU Langone Medical Center in New York. "It would be premature to say we've turned the corner but there's a lot going on in the pipeline that is quite promising,” said Ferris, who has been involved in trials for over 40 years. The Lilly and Biogen drugs block beta amyloid, a protein which causes toxic brain plaques considered a hallmark of the progressive brain disease. Lilly’s solanezumab showed signs of benefiting patients with a mild form of the disease in 2012. In March, Biogen’s aducanumab became the first experimental drug to significantly reduce beta amyloid in the brain and slow impairment in patients with mild disease. Both companies will present new data next week. "This year is different because multiple mechanisms are being explored and there's a tremendous revival of faith in the anti-amyloid approach," said Dr. Reisa Sperling, director of the Center for Alzheimer's Research at Harvard Medical School. Sperling's hope is that several drugs that work differently will prove effective and can be used together for "a 1-2-3 punch" to Alzheimer's, as combination treatments now control cancer and heart disease. An estimated 5 million people have the disease in the United States. The Alzheimer’s Association estimates that as many as 28 million Americans will develop the disease by midcentury and account for 25 percent of U.S. Medicare spending on the elderly in 2040. PROOF OF BENEFIT Biogen will present data on a 6 milligram dose of aducanumab on Wednesday, and researchers hope it will provide the right combination of effectiveness, with less of a brain-swelling side effect, than observed with other doses. If the 6 mg dose fails to show a significant improvement over placebo, the result could hurt Biogen shares. Researchers say they have improved the selection of patients for Alzheimer’s trials, making sure they are not suffering from another form of dementia by checking for beta amyloid, and by testing treatments before the disease becomes too advanced to have an impact. Biogen Chief Executive George Scangos said that until recently, over one-third of patients referred to trials of its drugs didn’t have Alzheimer’s “We're at a stage now where we understand the appropriate patient populations,” Scangos said on a conference call with reporters. Lilly estimates about 25 percent of patients in its previous Phase III trials were likely inappropriate candidates. An ongoing Phase III program will use brain imaging technology to ensure all patients have the amyloid plaque. On Wednesday, Lilly will present follow-up data from its earlier studies, showing whether those mildly affected patients who continued to take solanezumab for the last two years fared better than those who had initially taken a placebo for 18 months but then switched over to the actual drug. The Alzheimer’s meeting will also highlight an anti-inflammation drug called azeliragon abandoned years ago by Pfizer Inc when it proved ineffective after 12 months of study. Pfizer's tiny partner, privately held TransTech Pharma, continued to follow patients who had taken the drug and discovered their cognition had improved after 18 months - the primary goal of the study. The smaller company, which recently changed its name to vTv Therapeutics and aims to soon become public, began a late-stage study of azeliragon in April. Dr. Ronald Petersen, director of the Mayo Clinic’s Alzheimer’s Disease Research Center, agrees with Sperling that a multi-prong approach will be required to keep the disease at bay. “Another 5 to 8 years down the road, even before symptoms appear, we will be treating with a cocktail of therapies,” he said in an interview. (Reporting by Bill Berkrot and Ransdell Pierson in New York; Editing by Michele Gershberg and Andrew Hay)
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting
- E! News
The parents of Brian Laundrie, fiancé of late influencer Gabby Petito and a person of interest in her disappearance, have broken their silence.
Trump is suing his niece Mary Trump, The New York Times and three of its reporters.
- USA TODAY Sports - Golfweek
On Ryder Cup week, get to know these PGA Tour players' wives, girlfriends and families.
The friends even pretended to make out with an apple in one of the sensual campaign photos
John Walsh, the former host of 'America's Most Wanted,' questions if anyone actually saw Brian Laundrie in his home when his attorney said he was there
Brian Laundrie is considered a person of interest and has not been charged with any crime in the disappearance of Gabby Petito.
It's "not an agenda," the Watergate journalist told MSNBC's "Morning Joe."
- Miami Herald
Camila Cabello looked like she was starring in a music video for the updated version of an old ’60s song the other day.
- NBC Sports Philadelphia
The Sixers have reportedly talked with at least six teams around the league about a Ben Simmons trade - could this be the best offer available? By Adam Hermann
- The Daily Beast
LAPDA mom and daughter who allegedly posed as plastic surgery pros have been charged with murder after an aspiring adult film actress’ illegal butt augmentation surgery turned deadly.Libby Adame, 51, and Alicia Galaz, 23, were arrested Aug. 5 in Riverside, California, in connection with the death of 26-year-old Karissa Rajpaul, who died at a local hospital hours after she underwent the botched procedure.The Los Angeles Police Department told local outlets that the two women posed as specialists
- Good Morning America
A mom who is in the final stage in herfight against ovarian cancer is sharing the details of her "gritty story" to help educate and inform women. Dr. Nadia Chaudhri, a 44-year-old neuroscientist and professor from Montreal, Canada, has been battling Stage 3 ovarian cancer for the past year, undergoing a hysterectomy and several rounds of chemotherapy. In May, Chaudhri, the mom of a 6-year-old son, was hospitalized again and learned the cancer had returned, forcing her to tell her son that her cancer was now terminal.
Twitter users pluck the feathers out of Mike Lindell over his latest wild claim.
Police say four people found dead in SUV in Wisconsin were killed in Minnesota, suspect reportedly told his father he ‘snapped’
UPDATE: 9.21.21 9:10 p.m. Suspect Antoine Suggs, who was reportedly casually dating Nitosha Lee Flug-Presley, one of four people found […] The post Police say four people found dead in SUV in Wisconsin were killed in Minnesota, suspect reportedly told his father he ‘snapped’ appeared first on TheGrio.
- LA Times
Sen. Susan Collins says she would oppose Democrats' legislative response to Texas' new abortion law that bans the procedure at about six weeks of pregnancy.
Harvick's clash with Chase Elliott adds intriguing layer to next round of Cup Series playoffs.
Search warrant for Brian Laundrie: Gabby Petito's mom says conversations and texts with her appeared to show 'more and more tension' between couple
The tenor of some messages, followed by a lack of communication from Petito, is what led her mother to contact authorities, according to the warrant.
There's a chance you'll likely have "Fancy Like" by Walker Hayes stuck in your head after watching this.
Spider-Man: No Way Home remains the most talked-about unreleased MCU Phase 4 adventure of the year. That’s because the movie’s biggest secret leaked months ago, and Sony and Marvel weren’t able to contain it. Even those trying to avoid No Way Home spoilers at all cost will have a hard time doing it. There’s no … The post Sinister Six villains from ‘Spider-Man: No Way Home’ revealed in new leak appeared first on BGR.
Brian Laundrie's sister shared texts and postcards she said were from Gabby Petito, not long after a body was found in the search
Brian Laundrie's sister Cassie - the only family member to talk directly to media - shared postcards she said were from Gabby Petito's road trip.
- USA TODAY Sports - Golfweek
There's plenty of bonding at the biennial event, and not just among the players.
“This one, I think, we know the results already,” said former acting Solicitor General Neal Katyal.